BRIEF-U.S. FDA Extends Action Date For Expanded Label of Pfizer's Xeljanz In Ulcerative Colitis By Three Months
December 12, 2017 at 16:58 PM EST
* U.S. FOOD AND DRUG ADMINISTRATION EXTENDS ACTION DATE FOR XELJANZ® (TOFACITINIB) SUPPLEMENTAL NEW DRUG APPLICATION IN ULCERATIVE COLITIS BY THREE MONTHS